Frontier Biotechnologies Inc
SSE:688221
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Frontier Biotechnologies Inc
Current Portion of Long-Term Debt
Frontier Biotechnologies Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Frontier Biotechnologies Inc
SSE:688221
|
Current Portion of Long-Term Debt
¥59.6m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Current Portion of Long-Term Debt
¥565.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Current Portion of Long-Term Debt
¥800.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Current Portion of Long-Term Debt
¥228m
|
CAGR 3-Years
56%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Current Portion of Long-Term Debt
¥592.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
104%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Current Portion of Long-Term Debt
¥54.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Frontier Biotechnologies Inc
Glance View
Frontier Biotechnologies, Inc. engages in the research and development, production, and sale of medicines. The company is headquartered in Nanjing, Jiangsu and currently employs 495 full-time employees. The company went IPO on 2020-10-28. The firm's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The firm conducts its businesses within the China market and to overseas markets.
See Also
What is Frontier Biotechnologies Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
59.6m
CNY
Based on the financial report for Dec 31, 2024, Frontier Biotechnologies Inc's Current Portion of Long-Term Debt amounts to 59.6m CNY.
What is Frontier Biotechnologies Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
48%
Over the last year, the Current Portion of Long-Term Debt growth was -46%. The average annual Current Portion of Long-Term Debt growth rates for Frontier Biotechnologies Inc have been -37% over the past three years , 48% over the past five years .
